Alt stock price credit Suisse’s latest research note

Credit Suisse’s latest research note maintains an “Outperform” rating on alt stock price, projecting Q3 revenue growth at 9.4% YoY, outpacing the industry average growth projection of 6.1%. Leading cryptocurrencies jumped alongside stocks on Wednesday, as investors looked past government shutdown concerns. SAN DIEGO , Aug. 14, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT ) securities between August 10, 2023 and June 25, 2025 . Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases. Alt stock price volatility has increased 18% over the past month, according to CBOE data, signaling traders are pricing in upcoming catalysts. This aligns with an uptick in call option volume, reflecting bullish sentiment ahead of the firm’s late-August earnings release.